Alzheimer's & dementia (New York, N. Y.)Sep 22, 2026

Dementia progression and use of GLP-1 receptor drugs in people with mild memory problems and type 2 diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Sep 23, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with improved cardiovascular, kidney, and mortality outcomes in individuals with type 2 diabetes (T2D).

Multiple real-world studies suggest that GLP-1 RAs may reduce the risk of dementia onset in people with T2D.
The EVOKE/EVOKE+ randomized-controlled trials found that oral semaglutide did not slow cognitive decline in individuals with early Alzheimer's disease, with 86% of participants not having T2D.
It remains unclear if GLP-1 RA therapy could influence the progression to dementia in individuals with both T2D and mild cognitive impairment.

Simplified

In people with type 2 diabetes (T2D) without dementia, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improved cardiovascular, kidney, and mortality outcomes, with multiple real-world studies suggesting reduced risk of dementia onset. However, the EVOKE/EVOKE+ randomized-controlled trials (RCTs) found that oral semaglutide did not slow cognitive decline in individuals with early Alzheimer's disease (AD), most (86%) without T2D. It is unclear whether GLP-1 RA therapy influences progression to dementia in people with both T2D and mild cognitive impairment (MCI).

Full Text

Full text is available at the source.

View Full Text ↗

Featured in

GLP-1 Therapies

GLP-1 TherapiesIssue #56

Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it

The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated

1 week ago7 studies

GLP-1 drugs don't build habits — and that gap is costing patients their results

2 weeks ago7 studies

Semaglutide slowed aging and extended lifespan in older female mice

3 weeks ago7 studies

GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes

4 weeks ago7 studies

Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes

5 weeks ago7 studies

A once-daily pill beat placebo on weight loss — and it wasn't semaglutide

6 weeks ago7 studies

GLP-1 drugs work even without weight loss — and scientists are finally mapping why

7 weeks ago7 studies

Stop the drug, regain the weight: pooled data puts the average rebound at 7%

8 weeks ago7 studies

The brain region that explains why blocking and activating the same receptor both cause weight loss

9 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief